切换至 "中华医学电子期刊资源库"

中华胸部外科电子杂志 ›› 2014, Vol. 01 ›› Issue (01) : 8 -12. doi: 10.3877/cma.j.issn.2095-8773.2014.01.003

所属专题: 文献

论著

ⅠB期非小细胞肺癌不同亚组的预后研究
梁明强1, 朱勇1, 郭朝晖1, 郑炜1, 陈椿1,()   
  1. 1. 350000 福州,福建医科大学附属协和医院胸外科
  • 收稿日期:2014-09-20 出版日期:2014-11-28
  • 通信作者: 陈椿

Prognostic study of different subgroups of stage ⅠB non-small cell lung cancer

Mingqiang Liang1, Yong Zhu1, Zhaohui Guo1, Wei Zheng1, Chun Chen1,()   

  1. 1. Department of Thoracic Surgery, Union Hospital, Fujian Medical University, Fuzhou 35000, China
  • Received:2014-09-20 Published:2014-11-28
  • Corresponding author: Chun Chen
  • About author:
    Corresponding author: Chen Chun, Email:
引用本文:

梁明强, 朱勇, 郭朝晖, 郑炜, 陈椿. ⅠB期非小细胞肺癌不同亚组的预后研究[J]. 中华胸部外科电子杂志, 2014, 01(01): 8-12.

Mingqiang Liang, Yong Zhu, Zhaohui Guo, Wei Zheng, Chun Chen. Prognostic study of different subgroups of stage ⅠB non-small cell lung cancer[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2014, 01(01): 8-12.

目的

探讨ⅠB期非小细胞肺癌(NSCLC)不同亚组的预后因素。

方法

回顾性分析2008年3月至2013年12月间在福建医科大学附属协和医院胸外科接受手术切除的138例ⅠB期NSCLC患者的临床和随访资料。基于国际抗癌联盟(UICC)第七版肺癌分期,再根据肿瘤大小和脏层胸膜受侵情况,将患者细分为3组。ⅠB-a组:肿瘤直径≤3cm且脏层胸膜受侵;ⅠB-b组:3cm<肿瘤直径≤5cm且无脏层胸膜受侵;ⅠB-c组:3cm<肿瘤最大径≤5cm且脏层胸膜受侵。运用Kaplan-Meier生存分析和Cox比例风险模型,对影响NSCLC预后的因素进行分析。

结果

ⅠB期NSCLC患者3年总体生存率为88.1%,其中ⅠB-a组75例,ⅠB-b组32例,ⅠB-c组31例,3年生存率分别为92.0%、90.6%和74.1%,3组生存率比较差异有统计学意义(χ2=6.784,P=0.034)。单因素分析显示,无论患者的性别(χ2=0.103,P=0.567)、年龄(χ2=2.463,P=0.117)、手术切除方式(χ2=0.809,P=0.368)、是否接受术后辅助化疗(χ2=0.077,P=0.791),还是肿瘤的位置(χ2=0.091,P=0.674)、脏层胸膜是否受侵犯(χ2=0.085,P=0.771)均无统计学意义,而肿瘤大小(χ2=13.937,P=0.007)和分化程度(χ2=21.198,P=0.000)均有统计学意义。进一步多因素分析显示,只有肿瘤低分化(RR=0.027,95%CI为0.065~0.666,P=0.003)和中分化(RR=1.627,95%CI为1.020~2.597,P=0.008)有统计学意义。

结论

ⅠB期NSCLC不同亚组的3年生存率存在统计学差异,TNM分期对ⅠB期的定义可能仍有待改进。肿瘤大小及分化程度是影响患者3年生存率的重要因素,肿瘤中低分化是影响患者3年生存率的独立因素,而术后辅助化疗无影响,该结论有待进一步证实。

Objective

To investigate the prognostic factors of different subgroups of stage ⅠB non-small cell lung cancer (NSCLC).

Methods

The clinical and follow-up data of 138 cases of surgically resected stage ⅠB NSCLC in Department of Thoracic Surgery, Union Hospital, Fujian Medical University between March 2008 and December 2013 were retrospectively analyzed. Based on the seventh edition of lung cancer staging of the Union for International Cancer Control(UICC), then according to tumor size and visceral pleura invasion, the patients were divided into three groups: ⅠB-a group (diameter of tumor ≤ 3cm, with visceral pleura invasion), ⅠB-b group(3cm < diameter of tumor ≤ 5cm, without visceral pleura invasion) and ⅠB-c group (3cm < diameter of tumor ≤ 5cm, with visceral pleura invasion). Kaplan-Meier survival analysis and COX proportional hazard model were adopted to explore the factors affecting the prognosis of NSCLC.

Results

The 3-year overall survival of stage ⅠB NSCLC patients was 88.1%. There were 75 cases in ⅠB-a group, 32 cases in ⅠB-b group and 31 cases in ⅠB-c group, and the 3-year overall survival were 92.0%, 90.6% and 74.1%, respectively. There were significant differences in survival among three groups (χ2=6.784, P=0.034). Univariate analysis indicated that the gender (χ2=0.103, P=0.567), age (χ2=2.463, P=0.117), surgical resection(χ2=0.809, P=0.368), postoperative adjuvant chemotherapy (χ2=0.077, P=0.791), tumor′s location (χ2=0.091, P=0.674) and visceral pleura invasion(χ2=0.085, P=0.771) were not statistically significant, while tumor size (χ2=13.937, P=0.007) and tumor differentiation(χ2=21.198, P=0.000) were statistically significant. Further multivariate analysis revealed that only the poor differentiation (RR=0.027, 95% CI: 0.065-0.666, P=0.003) and moderate differentiation(RR=1.627, 95% CI: 1.020-2.597, P=0.008) were statistically significant.

Conclusion

There are significant differences in 3-year overall survival among subgroups of stage ⅠB NSCLC, and there is room for improvement in TNM staging for definition of ⅠB stage. Tumor size and tumor differentiation are important factors affecting the 3-year overall survival, moreover, the poor and moderate differentiation are independent factors, while the postoperative adjuvant chemotherapy has no effect on the 3-year overall survival. The findings need further investigations to confirm.

表1 138例ⅠB期NSCLC患者的一般资料及3年生存率
图1 ⅠB期非小细胞肺癌不同亚组的生存曲线
[1]
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging[J]. Chest, 1997,111(6):1718-1723.
[2]
Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2005, 130(1):160-165.
[3]
Kang JH, Kim KD, Chung KY. Prognostic value of visceral pleura invasion in non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2003,23(6):865-869.
[4]
Manac′h D, Riquet M, Medioni J, et al. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor[J]. Ann Thorac Surg, 2001,71(4):1088-1093.
[5]
David E, Thall PF, Kalhor N, et al. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size[J].Ann Thorac Surg, 2013,95(6):1872-1877.
[6]
Hung JJ, Wang CY, Huang MH, et al. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3cm or less: visceral pleural invasion did not influence overall and disease-free survival[J]. J Thorac Cardiovasc Surg, 2007,134(3):638-643.
[7]
Kawase A, Yoshida J, Miyaoka E, et al. Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a largescale nationwide database[J]. J Thorac Oncol, 2013,8(5):606-611.
[8]
Nitadori J, Colovos C, Kadota K, et al. Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma≤2cm: a proposal to reclassify T1 lung adenocarcinoma[J]. Chest, 2013,144(5):1622-1631.
[9]
代学利,申屠阳.Ⅰb期非小细胞肺癌患者手术预后因素分析[J].中国胸心血管外科临床杂志,2009,16(5):353-356.
[10]
毛锋,潘雁,李子明,等.Ⅰb期肺癌术后辅助化疗高风险因素分析[J].中国肺癌杂志,2014,(5):411-416.
[11]
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008 26(21):3552-3559.
[1] 应康, 杨璨莹, 刘凤珍, 陈丽丽, 刘燕娜. 左心室心肌应变对无症状重度主动脉瓣狭窄患者的预后评估价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 581-587.
[2] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[3] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[4] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[7] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[8] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗:10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[9] 卢艳军, 马健, 白鹏宇, 郭凌宏, 刘海义, 江波, 白文启, 张毅勋. 纳米碳在腹腔镜直肠癌根治术中253组淋巴结清扫的临床效果[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 473-477.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[12] 陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要